Provided are nucleic acids that encode decoy-resistant interleukin 18 (DR-18) polypeptides, as well as vectors and cells comprising such nucleic acids and cells that comprise such vectors. Cells encoding DR-18 polypeptides may be referred to as DR-18 armored cells. The nucleic acids may further encode a chimeric antigen receptor (CAR) or multiple CARs, including CARs that bind to antigens described herein. Methods are also provided, including methods of making the nucleic acids, vectors, and/or cells, as well as methods of use, such as employing the nucleic acids, vectors, and/or cells, in the treatment of a subject having cancer.

Provided are nucleic acids that encode decoy-resistant interleukin 18 (DR-18) polypeptides, as well as vectors and cells comprising such nucleic acids and cells that comprise such vectors. Cells encoding DR-18 polypeptides may be referred to as DR-18 armored cells. The nucleic acids may further encode a chimeric antigen receptor (CAR) or multiple CARs, including CARs that bind to antigens described herein. Methods are also provided, including methods of making the nucleic acids, vectors, and/or cells, as well as methods of use, such as employing the nucleic acids, vectors, and/or cells, in the treatment of a subject having cancer.

Disclosed herein are immune effector cells that are expanded and enriched for NKG2D expression and genetically modified to express chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill CD33-expressing and/or CD123-expressing cancers. In some embodiments, the immune effector cells are gamma-delta () T cells, Natural Killer (NK) cells, or a combination thereof.

The present disclosure provides adoptive T cell therapies that have improved architectures for targeting antigens and recruiting multimeric immune signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors or additional cells in combination therapies.

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and uses thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and uses thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

The present disclosure, at least in part, is based on the discovery of novel BCMA antibodies or antigen binding fragments thereof, and genetically modified cells (e.g., iNKT cells, CAR T cells, etc.) expressing chimeric antigen receptors comprising the anti-BCMA antibody or antigen binding fragment thereof demonstrate improved properties, including increased binding to BCMA, killing of BCMA-expressing cancer cells in vitro and in vivo; and enhanced persistent in a subject receiving the therapy.

The present disclosure, at least in part, is based on the discovery of novel BCMA antibodies or antigen binding fragments thereof, and genetically modified cells (e.g., iNKT cells, CAR T cells, etc.) expressing chimeric antigen receptors comprising the anti-BCMA antibody or antigen binding fragment thereof demonstrate improved properties, including increased binding to BCMA, killing of BCMA-expressing cancer cells in vitro and in vivo; and enhanced persistent in a subject receiving the therapy.

The present application provides formulations of enhanced antigen presenting cells (enhanced APCs), wherein the formulation comprises: the enhanced APCs comprising an antigen (e.g., a human papillomavirus (HPV) antigen) and one or more of the following: cryopreservation medium, hypothermic preservation medium, and human serum albumin. Also provided herein are methods of producing such formulations and the enhanced APCs.